<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22235356</PMID><DateCompleted><Year>2012</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1935-2735</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>PLoS neglected tropical diseases</Title><ISOAbbreviation>PLoS Negl Trop Dis</ISOAbbreviation></Journal><ArticleTitle>Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay.</ArticleTitle><Pagination><StartPage>e1447</StartPage><MedlinePgn>e1447</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1447</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pntd.0001447</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The envelope (E) protein of dengue virus (DENV) is the major target of neutralizing antibodies and vaccine development. While previous studies on domain III or domain I/II alone have reported several epitopes of monoclonal antibodies (mAbs) against DENV E protein, the possibility of interdomain epitopes and the relationship between epitopes and neutralizing potency remain largely unexplored.</AbstractText><AbstractText Label="METHODOLOGY/PRINCIPAL FINDINGS" NlmCategory="RESULTS">We developed a dot blot assay by using 67 alanine mutants of predicted surface-exposed E residues as a systematic approach to identify epitopes recognized by mAbs and polyclonal sera, and confirmed our findings using a capture-ELISA assay. Of the 12 mouse mAbs tested, three recognized a novel epitope involving residues (Q211, D215, P217) at the central interface of domain II, and three recognized residues at both domain III and the lateral ridge of domain II, suggesting a more frequent presence of interdomain epitopes than previously appreciated. Compared with mAbs generated by traditional protocols, the potent neutralizing mAbs generated by a new protocol recognized multiple residues in A strand or residues in C strand/CC' loop of DENV2 and DENV1, and multiple residues in BC loop and residues in DE loop, EF loop/F strand or G strand of DENV1. The predominant epitopes of anti-E antibodies in polyclonal sera were found to include both fusion loop and non-fusion residues in the same or adjacent monomer.</AbstractText><AbstractText Label="CONCLUSIONS/SIGNIFICANCE" NlmCategory="CONCLUSIONS">Our analyses have implications for epitope-specific diagnostics and epitope-based dengue vaccines. This high throughput method has tremendous application for mapping both intra and interdomain epitopes recognized by human mAbs and polyclonal sera, which would further our understanding of humoral immune responses to DENV at the epitope level.</AbstractText><CopyrightInformation>&#xa9; 2012 Lin et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Hong-En</ForeName><Initials>HE</Initials><AffiliationInfo><Affiliation>Institute of Microbiology, College of Medicine, National Taiwan University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Wen-Yang</ForeName><Initials>WY</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>I-Ju</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Pi-Chun</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Mei-Ying</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Jih-Jin</ForeName><Initials>JJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yi-Chieh</ForeName><Initials>YC</Initials></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Chih-Yun</ForeName><Initials>CY</Initials></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Chih-Hsuan</ForeName><Initials>CH</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jyh-Hsiung</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Gwong-Jen</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Han-Chung</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei-Kung</ForeName><Initials>WK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>01</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Negl Trop Dis</MedlineTA><NlmUniqueID>101291488</NlmUniqueID><ISSNLinking>1935-2727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003716" MajorTopicYN="N">Dengue Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016297" MajorTopicYN="N">Mutagenesis, Site-Directed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>11</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22235356</ArticleId><ArticleId IdType="pmc">PMC3250511</ArticleId><ArticleId IdType="doi">10.1371/journal.pntd.0001447</ArticleId><ArticleId IdType="pii">PNTD-D-11-00599</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gubler DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10:100&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11827812</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Dengue hemorrhagic fever: Diagnosis, treatment, prevention and control, 3rd ed. Geneva, Switzerland: 2009.</Citation></Reference><Reference><Citation>Whitehead SS, Blaney JE, Durbin AP, Murphy BR. Prospects for a dengue virus vaccine. Nat Rev Microbiol. 2007;5:518&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">17558424</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication, In: Knipe DM, Howley PM, editors. Fields virology, 5th ed. Philadelphia: Lippincott William &amp; Wilkins; 2007. pp. 1101&#x2013;1152.</Citation></Reference><Reference><Citation>Heinz FX, Stiasny K. Flavivirus membrane fusion. J Gen Virol. 2006;87:2755&#x2013;2766.</Citation><ArticleIdList><ArticleId IdType="pubmed">16963734</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph VB, Stollar V. Low pH-induced cell fusion in flavivirus-infected Aedes albopictus cell cultures. J Gen Virol. 1990;71:1845&#x2013;1850.</Citation><ArticleIdList><ArticleId IdType="pubmed">2167941</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427:313&#x2013;319.</Citation><ArticleIdList><ArticleId IdType="pubmed">14737159</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie JM, Westaway EGG. Assembly and maturation of the flavivirus Kunjin virus appear to occur in the rough endoplasmic reticulum and along the secretory pathway, respectively. J Virol. 2001;75:10787&#x2013;10799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114660</ArticleId><ArticleId IdType="pubmed">11602720</ArticleId></ArticleIdList></Reference><Reference><Citation>Welsch S, Miller S, Romero-Brey I, Merz A, Bleck CKE, et al. Composition and three-dimensional architecture of the dengue virus replication and assembly sites. Cell Host Microbe. 2009;5:365&#x2013;375.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7103389</ArticleId><ArticleId IdType="pubmed">19380115</ArticleId></ArticleIdList></Reference><Reference><Citation>Keelapang P, Sriburi R, Supasa S, Panyadee N, Songjaeng A, et al. Alterations of pr-M cleavage and virus export in pr-M junction chimeric dengue viruses. J Virol. 2004;78:2367&#x2013;2381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC369205</ArticleId><ArticleId IdType="pubmed">14963133</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray JM, Aaskov JG, Wright PJ. Processing of the dengue virus type 2 proteins prM and C-prM. J Gen Virol. 1993;74:175&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">8429301</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadler K, Allison SL, Schalich J, Heinz FX. Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997;71:8475&#x2013;8481.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC192310</ArticleId><ArticleId IdType="pubmed">9343204</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu IM, Zhang W, Holdaway HA, Li L, Kostyuchenko VA, et al. Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008;319:1834&#x2013;1837.</Citation><ArticleIdList><ArticleId IdType="pubmed">18369148</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlenghi I, Clarke M, Ruttan T, Allison SL, Schalich J, et al. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol Cell. 2001;7:593&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">11463384</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalich J, Allison SL, Stiasny K, Mandl SW, Kunz C, et al. Recombinant subviral particles from tick-borne encephalitis virus are fusogenic and provide a model system for studying flavivirus envelope glycoprotein functions. J Virol. 1996;70:4549&#x2013;4557.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190391</ArticleId><ArticleId IdType="pubmed">8676481</ArticleId></ArticleIdList></Reference><Reference><Citation>Stiasny K, Allison SL, Marchler-Bauer A, Kunz C, Heinz FX. Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus. J Virol. 1996;70:8142&#x2013;8147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC190891</ArticleId><ArticleId IdType="pubmed">8892942</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiou SS, Crill WD, Chen LK, Chang GJ. Enzyme-linked immunosorbent assays using novel Japanese encephalitis virus antigen improve the accuracy of clinical diagnosis of flavivirus infections. Clin Vaccine Immunol. 2008;15:825&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2394851</ArticleId><ArticleId IdType="pubmed">18337381</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis BS, Chang GJ, Cropp B, Roehrig JT, Martin DA, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol. 2001;75:4040&#x2013;4047.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC114149</ArticleId><ArticleId IdType="pubmed">11287553</ArticleId></ArticleIdList></Reference><Reference><Citation>Konishi E, Fujii A. Dengue type 2 virus subviral extracellular particles produced by a stably transfected mammalian cell line and their evaluation for a subunit vaccine. Vaccine. 2002;20:1058&#x2013;1067.</Citation><ArticleIdList><ArticleId IdType="pubmed">11803066</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberson JA, Crill WD, Chang GJ. Differentiation of West Nile and St. Louis encephalitis virus infections by use of noninfectious virus-like particles with reduced cross-reactivity. J Clin Microbiol. 2007;45:3167&#x2013;3174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2045342</ArticleId><ArticleId IdType="pubmed">17715375</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108:717&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4152842</ArticleId><ArticleId IdType="pubmed">11893341</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB. Pathogenesis of dengue: challenges to molecular biology. Science. 1988;239:476&#x2013;481.</Citation><ArticleIdList><ArticleId IdType="pubmed">3277268</ArticleId></ArticleIdList></Reference><Reference><Citation>Halstead SB, O'Rourke EJ. Antibody-enhanced dengue virus infection in primate leukocytes. Nature. 1977;265:739&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">404559</ArticleId></ArticleIdList></Reference><Reference><Citation>Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA. 2003;100:6986&#x2013;6991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165817</ArticleId><ArticleId IdType="pubmed">12759475</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Roehrig JT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol. 2001;75:7769&#x2013;7773.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC115016</ArticleId><ArticleId IdType="pubmed">11462053</ArticleId></ArticleIdList></Reference><Reference><Citation>Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. J Gen Virol. 1989;70:37&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">2543738</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Chang GJJ. Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes. J Virol. 2004;78:13975&#x2013;13986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC533943</ArticleId><ArticleId IdType="pubmed">15564505</ArticleId></ArticleIdList></Reference><Reference><Citation>Crill WD, Hughes HR, Delorey MJ, Chang GJ. Humoral immune responses of dengue fever patients using epitope-specific serotype-2 virus-like particle antigens. PLoS One. 2009;4:e4991.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659788</ArticleId><ArticleId IdType="pubmed">19337372</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett AD. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007;366:349&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">17719070</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromowski GD, Barrett ND, Barrett AD. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol. 2008;82:8828&#x2013;8837.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2519678</ArticleId><ArticleId IdType="pubmed">18562544</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisova O, Hardy F, Petit V, Bedouelle H. Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J Gen Virol. 2007;88:2387&#x2013;2397.</Citation><ArticleIdList><ArticleId IdType="pubmed">17698647</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin K, Purtha WE, Oliphant T, Nybakken GE, et al. Type and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81:12816&#x2013;12826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2169112</ArticleId><ArticleId IdType="pubmed">17881453</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, et al. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog. 2010;6:e1000823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848552</ArticleId><ArticleId IdType="pubmed">20369024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sukupolvi-Petty S, Austin SK, Engle M, Brien JD, Dowd KA, et al. Structure and function analysis of therapeutic monoclonal antibodies against dengue virus type 2. J Virol. 2010;84:9227&#x2013;9239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2937608</ArticleId><ArticleId IdType="pubmed">20592088</ArticleId></ArticleIdList></Reference><Reference><Citation>Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, et al. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol. 2010;84:10630&#x2013;10643.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950583</ArticleId><ArticleId IdType="pubmed">20702644</ArticleId></ArticleIdList></Reference><Reference><Citation>Goncalvez AP, Chien CH, Tubthong K, Gorshkova I, Roll C, et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol. 2008;82:7009&#x2013;7021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2446956</ArticleId><ArticleId IdType="pubmed">18480437</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogt MR, Moesker B, Goudsmit J, Jongeneelen M, Austin SK, et al. Human monoclonal antibodies against West Nile virus induced by natural infection neutralize at a postattachment step. J Virol. 2009;83:6494&#x2013;6507.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2698525</ArticleId><ArticleId IdType="pubmed">19386704</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YC, Huang HN, Lin CT, Chen YF, King CC, et al. Generation and characterization of monoclonal antibodies against dengue virus type 1 for epitope mapping and serological detection by epitope-based peptide antigens. Clin Vaccine Immunol. 2007;14:404&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1865613</ArticleId><ArticleId IdType="pubmed">17287314</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentry MK, Henchal EA, McCown JM, Brandt WE, Dalrymple JM. Identification of distinct antigenic determinants on dengue-2 virus using monoclonal antibodies. Am J Trop Med Hyg. 1982;31:548&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pubmed">6177259</ArticleId></ArticleIdList></Reference><Reference><Citation>Henchal EA, McCown JM, Burke DS, Seguin MC, Brandt WE. Epitopic analysis of antigenic determinants on the surface of dengue-2 virions using monoclonal antibodies. Am J Trop Med Hyg. 1985;34:162&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pubmed">2578750</ArticleId></ArticleIdList></Reference><Reference><Citation>Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology. 1992;187:480&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">1372140</ArticleId></ArticleIdList></Reference><Reference><Citation>Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998;246:317&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">9657950</ArticleId></ArticleIdList></Reference><Reference><Citation>Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg. 1988;38:172&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">3341519</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CY, Tsai WY, Lin SR, Kao CL, Hu SP, et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of domain II. J Virol. 2008;82:6631&#x2013;8843.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2447043</ArticleId><ArticleId IdType="pubmed">18448542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu HP, Hsieh SC, King CC, Wang WK. Characterization of retrovirus-based reporter viruses pseudotyped with the precursor membrane and envelope glycoproteins of four serotypes of dengue viruses. Virology. 2007;368:376&#x2013;387.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126519</ArticleId><ArticleId IdType="pubmed">17662331</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarova O, Kamberov EK, Margolis B. Generation of deletion and point mutations with one primer in a single cloning step. BioTechniques. 2000;29:970&#x2013;972.</Citation><ArticleIdList><ArticleId IdType="pubmed">11084856</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzumder R, Hu ZZ, Vinayaka CR, Sagripanti JL, Frost SDW, et al. Computational analysis and identification of amino acid sites in dengue E protein relevant to development of diagnostics and vaccines. Virus Genes. 2007;35:175&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pubmed">17508277</ArticleId></ArticleIdList></Reference><Reference><Citation>Thali M, Furman C, Ho DD, Robinson J, Tilley S, et al. Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol. 1992;66:5635&#x2013;5641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC289129</ArticleId><ArticleId IdType="pubmed">1380099</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann B, Vogt MR, Goudsmit J, Holdaway HA, Aksyuk AA, et al. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci U S A. 2010;107:18950&#x2013;18955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2973864</ArticleId><ArticleId IdType="pubmed">20956322</ArticleId></ArticleIdList></Reference><Reference><Citation>Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, et al. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat Struct Mol Biol. 2008;15:312&#x2013;317.</Citation><ArticleIdList><ArticleId IdType="pubmed">18264114</ArticleId></ArticleIdList></Reference><Reference><Citation>Zlatkovic J, Stiasny K, Heinz FX. Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice. J Virol. 2011;85:1994&#x2013;2003.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3067796</ArticleId><ArticleId IdType="pubmed">21147919</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahala WM, Kraus AA, Haymore LB, Accavitti-Loper MA, de Silva AM. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392:103&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2746956</ArticleId><ArticleId IdType="pubmed">19631955</ArticleId></ArticleIdList></Reference><Reference><Citation>Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8:271&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3884547</ArticleId><ArticleId IdType="pubmed">20833378</ArticleId></ArticleIdList></Reference><Reference><Citation>Dejnirattisai W, Jumnainsong A, Onsirisakul N, Fitton P, Vasanawathana S, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3837288</ArticleId><ArticleId IdType="pubmed">20448183</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliphant T, Nybakken GE, Austin SK, Xu Q, Bramson J, et al. Induction of epitope-specific neutralizing antibodies against West Nile virus. J Virol. 2007;81:11828&#x2013;11839.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2168772</ArticleId><ArticleId IdType="pubmed">17715236</ArticleId></ArticleIdList></Reference><Reference><Citation>Throsby M, Geuijen C, Goudsmit J, Bakker AQ, Korimbocus J, et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile virus. J Virol. 2006;80:6982&#x2013;6992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1489037</ArticleId><ArticleId IdType="pubmed">16809304</ArticleId></ArticleIdList></Reference><Reference><Citation>Nybakken GE, Oliphant T, Johnson S, Burke S, Diamond MS, et al. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature. 2005;437:764&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095628</ArticleId><ArticleId IdType="pubmed">16193056</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1:135&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656919</ArticleId><ArticleId IdType="pubmed">18005691</ArticleId></ArticleIdList></Reference><Reference><Citation>Diamond MS, Pierson TC, Fremont DH. The structural immunology of antibody protection against West Nile virus. Immunol Rev. 2008;225:212&#x2013;225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2646609</ArticleId><ArticleId IdType="pubmed">18837784</ArticleId></ArticleIdList></Reference><Reference><Citation>Burton DR, Saphire EO, Parren PW. A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol. 2001;260:109&#x2013;143.</Citation><ArticleIdList><ArticleId IdType="pubmed">11443871</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>